Atul Dandekar plans to sell 6,679 MAZE Therapeutics common shares valued at approximately $177,200 after restricted stock unit vesting. The issuer-mandated transaction includes shares needed for tax withholding, making the sale directly connected to Equity compensation settlement rather than a separately stated Investment decision.
Key Highlights
- The transaction followed restricted stock unit vesting on September 1, 2026.
- Morgan Stanley Smith Barney LLC is listed as the broker.
- The filing lists common-stock entries dated June 29, July 29 and August 28, 2026.
Atul Dandekar plans to sell 6,679 MAZE THERAPEUTICS, INC. (NASDAQ: MAZE) common shares valued at approximately $177,200. The transaction followed restricted stock unit vesting and includes an amount required to meet tax Withholding obligations.
6,679 Common Shares Tied to RSU Vesting
The transaction was reported on September 2, 2026, with restricted stock unit vesting recorded on September 1, 2026. The filing identifies the transaction as compensation-related and states that the restricted stock units were granted pursuant to an equity incentive award. The issuer mandated the sale, according to the reported transaction details. The filing lists common-stock entries including 7,500 shares dated June 29, 2026, with an amount of $210,150; 7,500 shares dated July 29, 2026, with an amount of $205,031.44; and 7,500 shares dated August 28, 2026, with an amount of $206,823.75.
Sale Includes Tax Withholding
The reported transaction includes the portion needed to satisfy tax withholding arising from the vesting and settlement of the restricted stock units. MAZE Therapeutics’ reported details identify the security as common stock. The transaction carries an approximate value of $177,200.




Please wait processing your request...